Sironax
维泰瑞隆
Sironax (维泰瑞隆) is a clinical-stage biotech company developing therapies for aging-related degenerative diseases. It raised a $200 million Series B in 2022 co-led by Yunfeng Capital and Gaorong Ventures, with follow-on participation from Temasek, ARCH Venture Partners and others, plus new investors including MSA Capital and CBC Group . In 2025 it announced a strategic agreement giving Novartis an exclusive option to acquire its proprietary brain delivery platform . Gaorong, which re-upped in that round, described Sironax as having built a strong R&D pipeline in degenerative diseases with promising early clinical signals .
elsewhere's corpus does not cover this subject in depth — the above is drawn from funding and deal announcements rather than dedicated reporting.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Geekplus, Saint Bella Go Public in Hong Kong; Deep Research, Design Agent Launched
See further into the future.
A Playbook for Billion-Dollar Drug Development: Navigating Uncharted Waters and Making Landfall | Ronghui
From Prozac to Gleevec — how to persevere on the long and winding road.
Multiple Innovative Companies Gain Global Recognition, Breakthroughs Achieved in Computational Biology, LiDAR, and Other Fields | Rongbao · July
Major events in July.
Vitaeon Therapeutics Completes $200 Million Series B Round to Develop Transformative Therapies for Aging-Related Degenerative Diseases
Transforming the treatment paradigm for age-related degenerative diseases, improving quality of life for millions of patients and families worldwide.
